Background: Epidemiological studies have revealed a protective effect of NSAIDs, which
principally target cyclooxygenase (COX)-1 and COX-2, on the development of colorectal …

Epidemiological and clinical studies suggest that non-steroidal anti-inflammatory drugs
(NSAIDs), including cyclooxygenase (COX)-2 selective inhibitors, reduce the risk of …

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risks for
esophageal, gastric and colon cancers as well as other solid tumors. The antitumor effect of …

Colorectal cancer (CRC) accounts for nearly 12% of newly diagnosed cancers in the United
States and is the second leading cause of cancer deaths (1, 2). Multidisciplinary research in …

Carcinoma of the colon or rectum represents one of the most common malignancies
worldwide with a higher prevalence in industrialized regions. Epidemiologic studies of …

Colorectal cancer (CRC) is a heterogeneous disease, including at least three major forms:
hereditary, sporadic and colitis-associated CRC. A large body of evidence indicates that …

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported to reduce the risk and
mortality of colorectal cancer (CRC) by inhibiting the activity of cyclooxygenase (COX). The …

Several lines of evidence suggest that the cyclooxygenase enzymes (specifically COX-2)
might be an important molecular target for the intervention of cancer at both early and late …

The regular use of various nonsteroidal anti‐inflammatory drugs (NSAIDs) was shown to
decrease the incidence of colorectal cancer. This effect is thought to be caused …

Multiple lines of evidence suggest that cyclooxygenase‐2 (COX‐2), an inducible form of
COX, represents a potential pharmacologic target to prevent cancer. Key data suggesting a …